CNS
Cohen & Steers Inc.
stock NYSE

Solvonis CEO: 'Strong tailwinds' for CNS as £1.3m fuels drug pipeline

Solvonis Therapeutics Raises £1.3 Million to Advance CNS Pipeline and Names New Broker

Solvonis CEO: 'Strong tailwinds' for CNS as £1.3m fuels drug pipeline

Solvonis Therapeutics Raises £1.3 Million to Advance CNS Pipeline and Names New Broker

Saniona – A Potentially Mispriced CNS Platform With Multiple Shots on Goal
1. Saniona is not a typical single-asset biotech. It has a diversified portfolio of internal programs (SAN2465, SAN2668 and SAN2219), partnered assets, future royalty streams and a proven ion-channel discovery platform capable of generating new drug candidates for years.
2. The company’s science has been validated through partnerships with Jazz Pharmaceuticals, Acadia Pharmaceuticals, Boehringer Ingelheim and AstronauTx, demonstrating industry recognition of its technology and drug discovery capabilities.
3. SAN2465 could become the company’s most valuable asset, targeting large CNS markets where successful Phase 1 data may support a licensing deal worth tens to hundreds of millions of dollars upfront and potentially billions in downstream value.
4. SAN2668 provides exposure to epilepsy and rare neurological diseases, an attractive area for biotech M&A where companies such as Longboard have achieved multi-billion-dollar valuations with a single clinical asset.
5. SAN2219 is often overlooked but could become a third meaningful value driver. If all three internal programs successfully complete Phase 1, Saniona would transition into a multi-asset clinical-stage CNS company, a shift that has historically attracted institutional investors and higher valuations.
6. SAN903 and Tesomet available for partnering, offers another source of non-dilutive value through upfront payments, milestones and royalties while allowing Saniona to focus resources on its priority CNS programs.
7. ACP-711 (Acadia) and SAN2355 (Jazz) provide significant long-term royalty optionality. If either program achieves commercial success, the resulting royalties could exceed Saniona’s current market capitalization multiple times.
8. Key near-term catalysts include CTA/IND approvals, Phase 1 initiations, positive clinical data, SAN903 partnering, milestone payments from existing partners and potential licensing deals for SAN2465. Each milestone reduces risk and enhances strategic value.
9. A realistic bull-case over the next 3-5 years includes all three internal candidates entering Phase 1, positive human data, at least one major licensing transaction, continued progress from Jazz and Acadia, and additional compounds emerging from the platform. This scenario could support a valuation far above today’s market capitalization.
10. The investment thesis is straightforward: the market largely values Saniona as a small development-stage biotech while assigning limited value to its pipeline, partnered assets, possible royalty and milestone streams, partnering opportunities and discovery engine. If execution remains strong, Saniona could become one of the most valuable independent CNS-focused biotech companies in the Nordic region over the next decade

Saniona – A Potentially Mispriced CNS Platform With Multiple Shots on Goal
1. Saniona is not a typical single-asset biotech. It has a diversified portfolio of internal programs (SAN2465, SAN2668 and SAN2219), partnered assets, future royalty streams and a proven ion-channel discovery platform capable of generating new drug candidates for years.
2. The company’s science has been validated through partnerships with Jazz Pharmaceuticals, Acadia Pharmaceuticals, Boehringer Ingelheim and AstronauTx, demonstrating industry recognition of its technology and drug discovery capabilities.
3. SAN2465 could become the company’s most valuable asset, targeting large CNS markets where successful Phase 1 data may support a licensing deal worth tens to hundreds of millions of dollars upfront and potentially billions in downstream value.
4. SAN2668 provides exposure to epilepsy and rare neurological diseases, an attractive area for biotech M&A where companies such as Longboard have achieved multi-billion-dollar valuations with a single clinical asset.
5. SAN2219 is often overlooked but could become a third meaningful value driver. If all three internal programs successfully complete Phase 1, Saniona would transition into a multi-asset clinical-stage CNS company, a shift that has historically attracted institutional investors and higher valuations.
6. SAN903 and Tesomet available for partnering, offers another source of non-dilutive value through upfront payments, milestones and royalties while allowing Saniona to focus resources on its priority CNS programs.
7. ACP-711 (Acadia) and SAN2355 (Jazz) provide significant long-term royalty optionality. If either program achieves commercial success, the resulting royalties could exceed Saniona’s current market capitalization multiple times.
8. Key near-term catalysts include CTA/IND approvals, Phase 1 initiations, positive clinical data, SAN903 partnering, milestone payments from existing partners and potential licensing deals for SAN2465. Each milestone reduces risk and enhances strategic value.
9. A realistic bull-case over the next 3-5 years includes all three internal candidates entering Phase 1, positive human data, at least one major licensing transaction, continued progress from Jazz and Acadia, and additional compounds emerging from the platform. This scenario could support a valuation far above today’s market capitalization.
10. The investment thesis is straightforward: the market largely values Saniona as a small development-stage biotech while assigning limited value to its pipeline, partnered assets, possible royalty and milestone streams, partnering opportunities and discovery engine. If execution remains strong, Saniona could become one of the most valuable independent CNS-focused biotech companies in the Nordic region over the next decade